Learn about targeted therapies for NSCLC

Targeted therapies used to treat NSCLC

Currently, three targeted therapies are approved to treat NSCLC. Tarceva (erlotinib) and Xalkori (crizotinib) are in pill form, while Avastin (bevacizumab) is administered through an IV. Targeted therapies have side effects, however they are often less severe than those from chemotherapy. Targeted therapies may be given alone or particularly in the case of Avastin, with chemotherapy. Targeted therapies are sometimes used as maintenace therapy.